|By 2025, Johnson & Johnson aims to achieve $4.5B Global Impact Spend with small and diverse suppliers, representing a 20% increase from 2020.
Advancing supplier diversity within Johnson & Johnson’s supply base makes a positive contribution to the economies in which the Company does business. It also enriches the ability to develop and deliver innovative medicines, products and solutions around the world. Partnering with an inclusive and diverse supplier base enables Johnson & Johnson to support economic inclusion and job creation for underserved populations through procurement activities.
|By 2025, expand the Johnson & Johnson Supplier Sustainability Program to include all suppliers; monitoring, engaging, collaborating on joint environmental, social and ethical obligations.
To create impact at scale, Johnson & Johnson must continue moving beyond monitoring compliance by engaging with suppliers and supporting wider industry efforts to improve transparency and share best practices. The Johnson & Johnson Sustainable Procurement Program helps expand supplier engagement to a more strategic level in which suppliers may partner with Johnson & Johnson to improve ESG impacts throughout the supply base.
|By 2025, demonstrate the capabilities to be ready to respond to a pandemic or epidemic threat within 12 – 18 months of an outbreak by generating data to support an emergency use submission to a stringent regulatory authority* for a preventive viral vaccine (as first demonstrated through Johnson & Johnson’s COVID-19 vaccine program).
*If granted emergency use by a SRA (Stringent Regulatory Authority), the goal would be to move forward to rapidly upscale manufacturing of the vaccine – potentially in parallel with SRA submission.
By 2025, Johnson & Johnson aims to enable global and open access to a vaccination monitoring platform for Global Health Security vaccination programs.
Johnson & Johnson aims to have the adoption of the endorsed vaccine monitoring platform by at least two countries by 2025.
|Johnson & Johnson will work to ensure it has the appropriate structures, systems and processes in place to enable access to the medicines and technologies most relevant for underserved populations in low- and middle-income countries.
Progress on the goal will be measured by the percentage of identified relevant assets from Johnson & Johnson Global Public Health and Janssen Infectious Diseases & Vaccines R&D pipeline with global access plans in place by 2025.
|Expand access to J&J’s more innovative treatments.|
Johnson & Johnson is committed to broadening access worldwide to HIV/AIDS therapy. As part of this commitment, by 2025 Johnson & Johnson aims to develop and enable HIV long-acting injectable (LAI) access solutions to provide care for people living with HIV in two countries in Resource-Limited Settings (RLS).
The new regimen’s availability in RLS would be significant. Because of advances in modern medicine, HIV should no longer be considered a death sentence; however, people with HIV must currently maintain strict, lifelong treatment regimens. Reducing the frequency of medication from daily to six times a year may make adherence easier on a long-term basis. Also, daily pill regimens may create stigma for those living with HIV, creating a barrier to seeking and adhering to treatment due to fear of disclosure. LAI regimens could provide solutions to these challenges.
|In 2018, Johnson & Johnson announced a 10-year tuberculosis (TB) goal of saving an estimated 1.8 million lives and preventing 12 million new infections; this includes a commitment of $500 million dedicated to R&D and delivery programs between 2018-2022 to accelerate global efforts to eliminate TB by 2030.
Additionally, Johnson & Johnson aims to develop at least one new TB drug and or/regimen by 2030.
This process will be conducted in accordance with stringent regulatory authority approvals of a new TB drug/regimen that reduces treatment length and is at least as effective and safe as the current recommended treatment.
Press Release: Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis, October 4, 2019
By 2025, enable access to bedaquiline to 700,000 cumulative patients, potentially averting 6,000,000 new multidrug-resistant TB (MDR-TB) infections. This goal will be measured by the number of cumulative patients receiving access to the bedaquiline molecule (branded and generic) globally from 2021 through the end of 2025.
Since 2018, Johnson & Johnson has been building on its collaboration with the Rwanda Ministry of Health to establish a proof-of-concept for an affordable model of mental health care that can be scaled to other African countries. A core element in this approach is to enable access to essential and innovative medicines for schizophrenia.
By 2025, Johnson & Johnson will have demonstrated the health, economic and social value and affordability of using paliperidone palmitate long-acting injectable to treat schizophrenia in Rwanda through a proof-of-concept.
|Johnson & Johnson aims to reduce the burden of obstetric fistula by supporting health workers and strengthening health systems, thus increasing the capacity to surgically heal women living with obstetric fistula.|
Johnson & Johnson is expanding its scope to include a focus on global surgery, in close collaboration with Johnson & Johnson Medical Device Companies. This includes obstetric fistula, a preventable and treatable birth injury caused by prolonged labor, which occurs most frequently in areas where it is difficult to access professional medical care.
By 2025, Johnson & Johnson’s goal is to reach 10,000 women living with obstetric fistula by strengthening the capacity of health workers and supporting delivery of surgical repair.
|Continue work to improve healthcare for women globally by sharing the top insights learned from real women across the globe.|
|By 2025, Johnson & Johnson will publish insights into best-practice healthcare for women based on real-world data of one million women.
By 2025, establish 10 supplier Partnerships for Good, collaborating with suppliers to create innovative solutions that drive environmental, social, and economic improvements.
By 2025, Johnson & Johnson is committed to donating up to one billion doses of VERMOX® CHEWABLE intestinal worms treatment to at-risk children in low- and middle-income countries. Intestinal worms are the most widespread of neglected tropical diseases and have a particularly damaging impact on the health and development of children.
|In July 2020, Johnson & Johnson announced a $100 million commitment to the founding of the AMR Action Fund, a collaboration with more than 20 leading pharmaceutical companies to collectively invest nearly $1 billion to address AMR. The Fund’s goal is to bring two to four new antibiotics to patients by the end of the decade.
Press Release: Statement attributed to Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson on the occasion of the launch of the AMR Action Fund, July 9, 2020
|In 2020, along with the Bill & Melinda Gates Foundation and 15 companies leading a pandemic research and development response effort, Johnson & Johnson signed a landmark Communiqué on Expanded Global Access commitment to ensure that people everywhere have access to COVID-19 innovations, regardless of their income level, to help accelerate the end of the pandemic. Timed to this, Johnson & Johnson committed to allocate up to 500 million vaccine doses to lower-income countries.
In 2021, Johnson & Johnson went beyond our planned commitments, pledging to make available, and commensurate with demand, supply up to a combined 900 million doses of the vaccine to the African Union and the COVAX Facility, alongside bilateral agreements with a number of LMICs by the end of 2022.
|Johnson & Johnson has committed to sourcing 100% of its electricity needs from renewable sources by 2025. The Company is already making strong progress towards this goal. At the end of 2020 54% of its global electricity came from renewable sources.
By 2030, Johnson & Johnson aims to achieve carbon neutrality in its operations (Scope 1 & 2 emissions) globally. This goal puts the Company on track to exceed what the science tells us is necessary for the business to contribute towards a 1.5-degree Celsius decarbonization roadmap.
Johnson & Johnson will work with suppliers to aim to reduce the Company’s upstream carbon footprint by 20% by 2030. Johnson & Johnson will launch new workstreams in carbon intensive procurement categories including logistics, chemicals, external manufacturing and packaging, among others. This Scope 3 goal aims to deliver nearly 2.5 times the carbon footprint reduction compared to that for owned operations.
Johnson & Johnson’s investment in employee health and well-being is built on the conviction that advancing health for humanity starts with protecting and advancing the health of its employees.
Johnson & Johnson aspires to have the healthiest workforce, further embedding a culture of health into every part of our organization and continuously expanding health and well-being programs globally, incorporating new thinking and technologies to help employees achieve their personal mind and body health goals.
Progress towards this goal will be measured through the percentage of Johnson & Johnson leaders accountable to achieving at or above the annual Healthiest Workforce Score (score benchmark being developed in 2021).
By 2025, Johnson & Johnson plans to engage a total of two million girls in science, technology, engineering, mathematics, manufacturing and design (STEM²D) activities in virtual or in-person activities led by employees in partnership with nonprofit partners.
Johnson & Johnson will further encourage its employees to play an active role in engaging with nonprofit partners to expose more girls to STEM²D activities, in the knowledge that advancing gender equality in technical professions will not only strengthen society, it will also build a stronger pipeline of diverse talent in these under-resourced professions.
By 2025, achieve 50% growth of Black and African American employees in management positions in the U.S.
By 2025, Johnson & Johnson aims to achieve 35% ethnic/racial diversity in management positions within the U.S.
|By 2025, Johnson & Johnson aims to achieve 50% of women in management positions globally.
By 2030, in an effort to strengthen health systems globally, the Johnson & Johnson Center for Health Worker Innovation will support and champion at least one million nurses, midwives and community health workers with skills, tools and growth opportunities. This will be measured by the number of nurses, midwives and community health workers reached globally.
|Accelerate innovation in areas of health security by supporting up to 30 start-up companies at any time through the BLUE KNIGHT™ initiative, which is anticipated through at least 2024. Currently there are 14 companies in the global BLUE KNIGHT™ portfolio, highlighting a diverse range of innovations, including potential solutions to combat COVID-19, focused on known and unknown health security threats.
Reach more than 2,000 people per year by conducting at least 1 Symposium and approximately 20 globally available education programs per year with content focused on elevating critical topics for start-up success in health security innovation. In 2020, more than 2,000 individuals globally attended 15 educational programs, which were offered in addition to the 2020 BLUE KNIGHT™ Symposium. The 2020 BLUE KNIGHT ™ Symposium successfully combined interaction and guidance from investors and later-stage entrepreneurs with programming that highlighted critical issues in the areas of diagnostics, data science, and bacterial pathogens to attract a global audience of nearly 1,500 innovators.
Recognizing it will take alignment of all our organizations to scale impact globally, we invite you to join the movement as a Steward of Inclusive Capitalism. Together, the collective action of Council members will contribute to a fairer, more inclusive and sustainable future for all people and our planet.